Drug Profile

Dihydroergotamine mesilate - Promius Pharma

Alternative Names: DFN-19

Latest Information Update: 26 Jul 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Promius Pharma
Class Antimigraines; Ergotamines; Mesylates; Small molecules
Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II Migraine

Most Recent Events

26 Jul 2022 Phase II development is ongoing USA (Intranasal) (Promius Pharma pipeline, July 20220)
01 May 2019 Phase-II clinical trials in Migraine in USA (Intranasal) before May 2019 (Promius Pharma pipeline, May 2019)
01 Jan 2019 Phase-I clinical trials in Migraine in USA (Intranasal) before January 2019 (Promius Pharma pipeline, January 2019)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com